Cleveland BioLabs announced strong survival results for its randomized, blinded, placebo-controlled efficacy study of CBLB502 in 179 non-human primates, or NHPs, conducted under Good Laboratory Practice (GLP) with elements of Good Clinical Practice, or GCP, as required by the U.S. FDA's Animal Rule. The study demonstrated with a high degree of statistical significance the dose-response relationship between the administration of CBLB502 and the survival of lethally irradiated animals, the study's primary endpoint.
A day after she refused to answer questions at a congressional hearing, Lois Lerner has been replaced as director …